Keyword: Juno Therapeutics
Kite will use the ZFN gene editing platform to create next-generation, off-the-shelf CAR-T therapies to cement its position in the cell therapy space.
Celgene agreed to buy CAR-T specialist Juno Therapeutics for around $9 billion in a deal instantly making it a big cheese in therapeutics.
Celgene is lining up another deal for CAR-T biotech Juno Therapeutics, according to several media reports.
Novartis poached Pfizer oncology head Liz Barrett, Ed Kaye became Stoke Therapeutics' CEO, and Perrigo hired Uwe Röhrhoff as CEO.
Johnson & Johnson is paying $350 million upfront to join forces with Legend as they look for a working “cure” for certain blood cancers.
Juno Therapeutics, which dumped its lead CAR-T program in March, has inked license agreements with Eli Lilly, OncoTracker and Fred Hutch.
CSO Hayden will leave as Teva restructures, Bayer R&D reorg sees Moeller in and Busch out for Shire, Shire and Biogen get experienced CFOs.
A new CAR-T approach controlled HIV spread and protected T cells from being attacked by HIV in mouse models.
Fred Hutchinson scientists have identified biomarkers associated with dangerous side effects possible in cancer patients treated with CAR-T cells.
Juno's top-level executives are being investigated about whether they failed shareholders by not telling them more about a trial's fatalities.